Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Robin J. Dart & Peter M. Irving. (2017) Optimising use of thiopurines in inflammatory bowel disease. Expert Review of Clinical Immunology 13:9, pages 877-888.
Read now
Read now
Marianne Kiszka-Kanowitz, Klaus Theede & Anette Mertz-Nielsen. (2016) Randomized clinical trial: a pilot study comparing efficacy of low-dose azathioprine and allopurinol to azathioprine on clinical outcomes in inflammatory bowel disease. Scandinavian Journal of Gastroenterology 51:12, pages 1470-1475.
Read now
Read now
S. Almer. (2010) Novel Strategies in the Thiopurine Treatment of Inflammatory Bowel Disease. Nucleosides, Nucleotides & Nucleic Acids 29:4-6, pages 267-277.
Read now
Read now
Articles from other publishers (42)
Peter M. Irving & Krisztina B. Gecse. (2022) Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives. Gastroenterology 162:5, pages 1512-1524.
Crossref
Crossref
Albert J. Czaja. (2020) Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis. Alimentary Pharmacology & Therapeutics 51:12, pages 1286-1304.
Crossref
Crossref
Sara van Gennep, Kadère Konté, Berrie Meijer, Martijn W. Heymans, Geert R. D’Haens, Mark Löwenberg & Nanne K. H. de Boer. (2019) Systematic review with meta-analysis: risk factors for thiopurine-induced leukopenia in IBD. Alimentary Pharmacology & Therapeutics 50:5, pages 484-506.
Crossref
Crossref
Sheng Zhang Lim & Eng Wee Chua. (2018) Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring. Frontiers in Pharmacology 9.
Crossref
Crossref
Sandra Bohn Thomsen, Marianne Kiszka-Kanowitz, Klaus Theede, Lise Lotte Gluud & Anette Mertz Nielsen. (2018) Optimized thiopurine therapy before withdrawal of anti-tumour necrosis factor-α in patients with Crohn’s disease. European Journal of Gastroenterology & Hepatology 30:10, pages 1155-1158.
Crossref
Crossref
Luc J. J. Derijks, Dennis R. Wong, Daniel W. Hommes & Adriaan A. van Bodegraven. (2018) Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease. Clinical Pharmacokinetics 57:9, pages 1075-1106.
Crossref
Crossref
Vid Mlakar, Patricia Huezo-Diaz Curtis, Chakradhara Satyanarayana Uppugunduri, Maja Krajinovic & Marc Ansari. (2016) Pharmacogenomics in Pediatric Oncology: Review of Gene—Drug Associations for Clinical Use. International Journal of Molecular Sciences 17:9, pages 1502.
Crossref
Crossref
Shi Sum Poon, Rebecca Asher, Richard Jackson, Andrew Kneebone, Paul Collins, Chris Probert, Martyn Dibb & Sreedhar Subramanian. (2015) Body Mass Index and Smoking Affect Thioguanine Nucleotide Levels in Inflammatory Bowel Disease. Journal of Crohn's and Colitis 9:8, pages 640-646.
Crossref
Crossref
Steven Chung Ming Fong, Paul Andrew Blaker, Monica Arenas-Hernandez, Anthony Marin Marinaki & Jeremy David Sanderson. (2015)
Getting the best out of thiopurine therapy: thiopurine
S
-methyltransferase and beyond
. Biomarkers in Medicine 9:1, pages 51-65.
Crossref
Crossref
Edouard Louis, Peter Irving & Laurent Beaugerie. (2014) Use of azathioprine in IBD: modern aspects of an old drug. Gut 63:11, pages 1695-1699.
Crossref
Crossref
Margien L Seinen, Nanne KH de Boer, Adriaan A van Bodegraven, Stephen B Hanauer & Frank Hoentjen. (2014) Allopurinol–thiopurine combination therapy in inflammatory bowel disease. Clinical Investigation 4:10, pages 873-879.
Crossref
Crossref
Peter M. Irving. (2014) Can we get more from our current treatments?. Best Practice & Research Clinical Gastroenterology 28:3, pages 451-463.
Crossref
Crossref
Gerassimos J. Mantzaris. (2014) When can we cure Crohn's?. Best Practice & Research Clinical Gastroenterology 28:3, pages 519-529.
Crossref
Crossref
Peter M. Irving. (2014) Are We Using and Monitoring Thiopurines and Biologics Optimally?. Digestive Diseases 32:4, pages 410-418.
Crossref
Crossref
Salma Melaouhia, Monia Fékih, Henda Ferchichi, Houda Bouissorra, Nadia Ben Mustapha, Jalel Boubaker, Azza Filali, Mohamed Lakhal & Anis Klouz. (2013) Y a-t-il intérêt à doser les métabolites de l’azathioprine chez les malades ayant une maladie inflammatoire chronique de l’intestin?. Therapies 68:5, pages 313-320.
Crossref
Crossref
P.A. Blaker, M. Arenas-Hernandez, M.A. Smith, E.A. Shobowale-Bakre, L. Fairbanks, P.M. Irving, J.D. Sanderson & A.M. Marinaki. (2013) Mechanism of allopurinol induced TPMT inhibition. Biochemical Pharmacology 86:4, pages 539-547.
Crossref
Crossref
N. A. Kennedy, T. L. Asser, R. E. Mountifield, M. P. Doogue, J. M. Andrews & P. A. Bampton. (2013) Thiopurine metabolite measurement leads to changes in management of inflammatory bowel disease. Internal Medicine Journal 43:3, pages 278-286.
Crossref
Crossref
M. Smith, P. Blaker, C. Patel, A. Marinaki, M. Arenas, E. Escuredo, S. Anderson, P. Irving & J. Sanderson. (2013) The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic. International Journal of Clinical Practice 67:2, pages 161-169.
Crossref
Crossref
Adele Corrigan, Monica Arenas-Hernandez, Paul Blaker, Jeremy Sanderson & Anthony Marinaki. (2012) Let’s get personal: predicting thiopurine and fluoropyrimidine toxicity. Personalized Medicine 9:8, pages 859-870.
Crossref
Crossref
Paul Andrew BlakerMonica Arenas-Hernandez, Anthony Marin Marinaki & Jeremy David Sanderson. (2012) The pharmacogenetic basis of individual variation in thiopurine metabolism. Personalized Medicine 9:7, pages 707-725.
Crossref
Crossref
Lennard P.L. Gilissen, Dennis R. Wong, Leopold G.J.B. Engels, Jörgen Bierau, Jaap A. Bakker, Aimée D.C. Paulussen, Mariëlle J. Romberg-Camps, Arnold Stronkhorst, Paul Bus, Laurens P. Bos, Piet M. Hooymans, Reinhold W. Stockbrügger, Cees Neef & Ad A.M. Masclee. (2012) Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy. Journal of Crohn's and Colitis 6:6, pages 698-707.
Crossref
Crossref
R. van Egmond, P. Chin, M. Zhang, C. W. Sies & M. L. Barclay. (2012)
High
TPMT
enzyme activity does not explain drug resistance due to preferential 6‐methylmercaptopurine production in patients on thiopurine treatment
. Alimentary Pharmacology & Therapeutics 35:10, pages 1181-1189.
Crossref
Crossref
Jack H. Jacobsen, Kjeld Schmiegelow & Jacob Nersting. (2012) Liquid chromatography–tandem mass spectrometry quantification of 6-thioguanine in DNA using endogenous guanine as internal standard. Journal of Chromatography B 881-882, pages 115-118.
Crossref
Crossref
Liang Ding, Fang-bin Zhang, Hui Liu, Xiang Gao, Hui-chang Bi, Xue-ding Wang, Bai-li Chen, Yu Zhang, Li-zi Zhao, Guo-ping Zhong, Pin-jin Hu, Min-hu Chen & Ming Huang. (2012) Hypoxanthine guanine phosphoribosyltransferase activity is related to 6-thioguanine nucleotide concentrations and thiopurine-induced leukopenia in the treatment of inflammatory bowel disease. Inflammatory Bowel Diseases 18:1, pages 63-73.
Crossref
Crossref
Melissa L. Haines, Yousef Ajlouni, Peter M. Irving, Miles P. Sparrow, Rosemary Rose, Richard B. Gearry & Peter R. Gibson. (2011) Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflammatory Bowel Diseases 17:6, pages 1301-1307.
Crossref
Crossref
P. de Graaf, R.M. Vos, N.H.K. de Boer, A. Sinjewel, B. Jharap, C.J.J. Mulder, A.A. van Bodegraven & A.I. Veldkamp. (2010) Limited stability of thiopurine metabolites in blood samples: Relevant in research and clinical practise. Journal of Chromatography B 878:19, pages 1437-1442.
Crossref
Crossref
Nicole Jourdil, Xavier Fonrose, Roselyne Boulieu & Françoise Stanke-Labesque. (2010) Suivi thérapeutique pharmacologique des 6-thioguanine nucléotides dans les maladies inflammatoires cryptogéniques de l’intestin : intérêt et limites. Therapies 65:3, pages 177-186.
Crossref
Crossref
L T Ford & J D Berg. (2010) Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come. Journal of Clinical Pathology 63:4, pages 288-295.
Crossref
Crossref
Jared T. Hagaman, Brent W. Kinder & Mark H. Eckman. (2010) Thiopurine S-Methyltranferase Testing in Idiopathic Pulmonary Fibrosis: A Pharmacogenetic Cost-Effectiveness Analysis. Lung 188:2, pages 125-132.
Crossref
Crossref
Jenny E Higgs, Katherine Payne, Chris Roberts & William G Newman. (2010) Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications?. Pharmacogenomics 11:2, pages 177-188.
Crossref
Crossref
Ulf Hindorf, Khatoon Jahed, Annika Bergquist, Hans Verbaan, Hanne Prytz, Sven Wallerstedt, Mårten Werner, Rolf Olsson, Einar Björnsson, Curt Peterson & Sven H.C. Almer. (2010) Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis. Journal of Hepatology 52:1, pages 106-111.
Crossref
Crossref
L. A. CHRISTENSEN, J. F. DAHLERUP, M. J. NIELSEN, J. F. FALLINGBORG & K. SCHMIEGELOW. (2008) Azathioprine treatment during lactation. Alimentary Pharmacology & Therapeutics 28:10, pages 1209-1213.
Crossref
Crossref
R L Roberts, R B Gearry, M L Barclay & M A Kennedy. (2006) IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance. The Pharmacogenomics Journal 7:5, pages 312-317.
Crossref
Crossref
Max Reinshagen, Ekkehard Schütz, Victor W Armstrong, Christoph Behrens, Christian von Tirpitz, Andreas Stallmach, Hans Herfarth, Jürgen Stein, Peter Bias, Guido Adler, Maria Shipkova, Wolfgang Kruis, Michael Oellerich & Nicolas von Ahsen. (2007) 6-Thioguanine Nucleotide–Adapted Azathioprine Therapy Does Not Lead to Higher Remission Rates Than Standard Therapy in Chronic Active Crohn Disease: Results from a Randomized, Controlled, Open Trial. Clinical Chemistry 53:7, pages 1306-1314.
Crossref
Crossref
Ahmed Morales, Sandhya Salguti, Chuan L. Miao & James D. Lewis. (2007) Relationship Between 6-Mercaptopurine Dose and 6-Thioguanine Nucleotide Levels in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases 13:4, pages 380-385.
Crossref
Crossref
Javier P. Gisbert, Pilar Niño, Luis Rodrigo, Carlos Cara & Luis G. Guijarro. (2006) Thiopurine Methyltransferase (TPMT) Activity and Adverse Effects of Azathioprine in Inflammatory Bowel Disease: Long-Term Follow-Up Study of 394 Patients. The American Journal of Gastroenterology 101:12, pages 2769-2776.
Crossref
Crossref
Javier P. Gisbert, Yago González-Lama & José Maté. (2006) Monitorización de la tiopurina metiltransferasa y de los metabolitos tiopurínicos para optimizar el tratamiento con azatioprina en la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 29:9, pages 568-583.
Crossref
Crossref
L. J. J. DERIJKS, L. P. L. GILISSEN, P. M. HOOYMANS & D. W. HOMMES. (2006) Review article: thiopurines in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics 24:5, pages 715-729.
Crossref
Crossref
Mark T. Osterman, Rabi Kundu, Gary R. Lichtenstein & James D. Lewis. (2006) Association of 6-Thioguanine Nucleotide Levels and Inflammatory Bowel Disease Activity: A Meta-Analysis. Gastroenterology 130:4, pages 1047-1053.
Crossref
Crossref
Luc J. J. Derijks & Daniel W. Hommes. (2006) Thiopurines in inflammatory bowel disease: New strategies for optimization of pharmacotherapy?. Current Gastroenterology Reports 8:2, pages 89-92.
Crossref
Crossref
R. B. Gearry, M. L. Barclay, R. L. Roberts, J. Harraway, M. Zhang, L. S. Pike, P. M. George & C. M. Florkowski. (2005) Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice. Internal Medicine Journal 35:10, pages 580-585.
Crossref
Crossref
John A Duley & Timothy H. J Florin. (2005) Thiopurine Therapies. Therapeutic Drug Monitoring 27:5, pages 647-654.
Crossref
Crossref